Skip to main content

This job has expired

Value Evidence Lead Pneumococcal Vaccines

Employer
GSK
Location
Philadelphia, Pennsylvania; Rockville, Maryland
Salary
Competitive
Closing date
Oct 3, 2022

View more

Discipline
Health Sciences, Vaccine Research
Organization Type
All Industry, Pharma
Vaccines Value Evidence Lead (Director) Pneumococcal Vaccines

Patient-focused Research and Development (R&D) is the heart of our business. GSK has a strong history and expertise in vaccines, and we are staying at the forefront of innovation in this field.

For many years, vaccines have been used mainly to prevent diseases caused by infections, mostly in infants and children. Today, we are focused on developing vaccines for all stages of life, and we believe vaccines can also be used successfully to treat diseases and therefore be therapeutic.

These innovation trends have a strong impact on what we do in Research and Development. We take the best science, with the most impactful technologies and combine it with our GSK culture. Next to our existing portfolio of prophylactic vaccines and moving into the field of therapeutic vaccines, our R&D programme focuses on vaccines for diseases such as RSV, Meningitis and Pneumococcal disease. Another part of R&D targets diseases particularly prevalent in the developing world, including the World Health Organisation's priority diseases - tuberculosis and malaria.

As part of the R&D organisation, the Vaccines Value Evidence team drives the identification, strategic planning and development of the Value Evidence requirements from early to late development and lifecycle management. The GSK Pneumococcal Vaccines Value Evidence Lead is accountable to drive the Global Value Evidence Generation and project work for the GSK Pneumococcal Vaccines portfolio in development and life cycle management to which matrix leadership and direct reports are deployed including line management and mentoring.

This role is essential to ensure that the Pneumococcal Vaccines portfolio and in particular the development of Pneumococcal Vaccines is supported by scientifically credible, high quality evidence that drives competitiveness and strong evidence-based product positioning, value propositions and value-based pricing. The role is critical for the alignment of Value Evidence generation with the evidentiary requirements of customers responsible for marketing authorization, recommendation (e.g. National Immunization Technical Advisory Groups - NITAGs) and reimbursement leading to successful patient access, product use and commercial success.

This role requires leadership of a matrix team drawn from global platforms to develop the options for evidence generation requiring a strong ability to manage complex matrix relationships and interdependencies. In addition to strategic leadership, this position also facilitates alignment and visibility to the activities conducted globally, regionally and locally.

You will be responsible to:
  • Lead and ensure alignment across the matrix Vaccines Value Evidence Team for the Pneumococcal Development assets, drawn from Value Evidence and Outcomes (VEO; Real World Analytics, Patient Centric Outcomes, Epidemiology) and other R&D platforms (Clinical Development, Statistics, Medical Affairs, regional and LOC Health Outcomes and Market Access) to deliver the Value Evidence Generation strategic options, plans and execution which fall under the Integrated Evidence and the Integrated Asset Plan.
  • Lead the external dialogue for Pneumococcal Development on the global scientific Value Evidence requirements with recommendation and reimbursement bodies including seeking formal scientific advice to National Immunization Technical Advisory Committees (NITAGs) and Health Technology Assessment (HTA) bodies.
  • Partner with a complex set of global, regional and local internal stakeholders including Vaccine Development Leads, Global Vaccine Commercial Leads, Epidemiology and Clinical Scientists, global and local Medical Affairs, local Market Access within GSK etc. and ensure appropriate representation at project governance level.
  • Lead, manage, and develop direct reports to develop high quality value evidence strategies, optimizing resources in alignment with priorities, and ensuring timely, robust execution of evidence for the Pneumococcal Vaccines Portfolio.
  • Deliver the Pneumococcal Vaccines Portfolio VEO materials to inform internal governance decision making and support the regions and priority LOCs on recommendation and reimbursement activities.
  • Lead scientific robust value evidence studies (e.g. cost-of-illness, healthcare resource utilization, utility and quality of life assessments using Patient Reported Outcomes (PROs), Real World Evidence (RWE), economic and public health impact modelling, indirect study comparisons, etc) ensuring scientific robustness and compliance with necessary regulations for quality and disclosure.
  • Partner with the VEO Patient Centric Outcomes and VEO Real World Analytics teams to ensure the operational delivery of Patient Reported Outcomes (PROs) and Real World Evidences (RWE) aligned with the Target Vaccine Profile expectations.
  • Lead annual Pneumococcal Development Value Evidence budget forecasting and activity prioritization while effectively managing projects and budgets for Human Subject Research (HSR) and non-HSR activities.
  • Develop and maintain excellent network contacts with industry associations, professional societies and external Health Economics and Public Health experts/thought leaders to keep abreast and bring GSK's perspective to significant developments in the field.
  • Integrate excellent understanding of the evolving global NITAG, Health Technology Assessment, policy decision maker and payer environment, including recommendation, reimbursement, pricing, and access.


Why you?

Basic Qualifications:

We are looking for professionals with these required skills to achieve our goals:
  • Significant experience (8-10 years) in health economics, health outcomes, market access or an aligned discipline/function in a consulting, pharmaceutical industry or academic environment.


Preferred Qualifications:

If you have the following characteristics it would be a plus:
  • Experience in Pneumococcal vaccines
  • Experience in the development (Ph3) and launch of vaccines
  • Experience in the US market, preferably in the field of vaccines
  • Experience in managing direct reports
  • PhD in a relevant discipline
  • Experience in recommendation/reimbursement (NITAG/HTA) dossier submissions including experience in discussing and negotiating with payers and/or public health authorities leading to successful recommendations and reimbursement in multiple markets in the vaccines field.
  • Pharmaceutical experience that includes:
    • Experience in vaccines
    • Above country experience
    • Effective leadership leading cross-functional teams to deliver an integrated plan and driving consensus decision making.
  • In-depth knowledge about vaccines market access pathways, recommendation and reimbursement in the US and EU-5
  • Authored publications in infectious diseases and/or vaccines value evidence discipline.


Our department:

R&D

Patient-focused Research and Development (R&D) is the heart of our business. GSK has a strong history and expertise in vaccines, and we are staying at the forefront of innovation in this field.

For many years, vaccines have been used mainly to prevent diseases caused by infections, mostly in infants and children. Today, we are focused on developing vaccines for all stages of life, and we believe vaccines can also be used successfully to treat diseases and be therapeutic.

These innovation trends have a strong impact on what we do in Research and Development. We take the best science, with the most impactful technologies and combine it with our GSK culture. Next to our existing portfolio of prophylactic vaccines and moving into the field of therapeutic vaccines, our R&D programme focuses on vaccines for diseases such as RSV, Meningitis and Pneumococcal. Another part of R&D targets diseases particularly prevalent in the developing world, including the World Health Organisation's priority diseases - tuberculosis and malaria.

Why GSK

At GSK, we have already delivered unprecedented change over the past four years, improving R&D, becoming a leader inConsumer Health, strengthening our leadership, and transforming our commercial execution. Now, we're making the biggestchanges we've made to our business in over 20 years. We're on track to separate and create two new companies in 2022: New GSK with a leading portfolio of vaccines and specialty medicines as well as R&D based on immune system and geneticsscience; and a new world-leading consumer healthcare company of loved and trusted brands.

With new ambition comes new purpose. For New GSK, this is to unite science, talent and technology to get ahead of diseasetogether - all with the clear ambition of delivering human health impact; stronger and more sustainable shareholder returns; andas a new GSK where outstanding people thrive.

Getting ahead means preventing disease as well as treating it. How we do all this is through our people and our culture. A culturethat is ambitious for patients - so we deliver what matters better and faster; accountable for impact - with clear ownership ofgoals and support to succeed; and where we do the right thing . So, if you're ready to improve the lives of billions, join us at thisexciting moment in our journey. Join our challenge to get Ahead Together.

*Li-GSK

If you require an accommodation or other assistance to apply for a job at GSK, please contact the GSK Service Centre at 1-877-694-7547 (US Toll Free) or +1 801 567 5155 (outside US).

GSK is an Equal Opportunity Employer and, in the US, we adhere to Affirmative Action principles. This ensures that all qualified applicants will receive equal consideration for employment without regard to race, color, national origin, religion, sex, pregnancy, marital status, sexual orientation, gender identity/expression, age, disability, genetic information, military service, covered/protected veteran status or any other federal, state or local protected class.

At GSK, the health and safety of our employees are of paramount importance. As a science-led healthcare company on a mission to get ahead of disease together, we believe that supporting vaccination against COVID-19 is the single best thing we can do in the US to ensure the health and safety of our employees, complementary workers, workplaces, customers, consumers, communities, and the patients we serve.

GSK has made the decision to require all US employees to be fully vaccinated against COVID-19, where allowed by state or local law and where vaccine supply is readily available. The only exceptions to this requirement are employees who are approved for an accommodation for religious, medical or disability-related reasons.

Important notice to Employment businesses/ Agencies

GSK does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact GSK's commercial and general procurement/human resources department to obtain prior written authorization before referring any candidates to GSK. The obtaining of prior written authorization is a condition precedent to any agreement (verbal or written) between the employment business/ agency and GSK. In the absence of such written authorization being obtained any actions undertaken by the employment business/agency shall be deemed to have been performed without the consent or contractual agreement of GSK. GSK shall therefore not be liable for any fees arising from such actions or any fees arising from any referrals by employment businesses/agencies in respect of the vacancies posted on this site.

Please note that if you are a US Licensed Healthcare Professional or Healthcare Professional as defined by the laws of the state issuing your license, GSK may be required to capture and report expenses GSK incurs, on your behalf, in the event you are afforded an interview for employment. This capture of applicable transfers of value is necessary to ensure GSK's compliance to all federal and state US Transparency requirements. For more information, please visit GSK's Transparency Reporting For the Record site.

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert